Compare

Adlai Nortye Ltd. ADS/$ANL

1D1W1M3M6MYTD1Y5YMAX

About Adlai Nortye Ltd. ADS

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Ticker
$ANL
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Singapore, Singapore
Website
www.adlainortye.com

ANL Metrics

BasicAdvanced
$617M
-
-$0.56
1.12
-

What the Analysts think about ANL

Analyst ratings (Buy, Hold, Sell) for Adlai Nortye Ltd. ADS stock.
Analyst projections of the future price of Adlai Nortye Ltd. ADS stock.

Bulls say / Bears say

AN9025 is being tested on both once-daily and once-weekly schedules in a global Phase I trial. Management has reported encouraging early pharmacokinetic findings and preliminary activity, with a fuller daily-arm readout expected in the first half of 2027. (Adlai Nortye, StockAnalysis)
AN4035 has entered human testing, and FDA clearance allows its Phase I trial to expand into the United States. Lilly and Merck will supply cetuximab at no cost for combination-trial sites, supporting a distinctive RAS-targeted ADC approach. (SEC, GlobeNewswire)
The company reported $231.9 million in cash and short-term investments at the end of June 2026, and management said this should fund development through 2028. That gives it room to advance its clinical programmes towards key data readouts without an immediate need to raise more capital. (SEC, StockAnalysis)
The main RAS candidates remain in early-stage trials, with initial AN9025 data expected in the first half of 2027 and AN4035 data in the second half. Until then, investors have little human evidence to judge whether either programme works safely and effectively. (Adlai Nortye, SEC)
AN9025's claimed potency advantage comes from preclinical work, not established patient results. Management has acknowledged that its differentiation depends on showing competitive efficacy and tolerability in people, leaving the best-in-class case unproven. (StockAnalysis)
The 2026 financings strengthened the balance sheet but also increased Class A shares outstanding from 103.0 million at year-end 2025 to 176.2 million by June 2026, diluting existing holders. A filing also registered resale of a substantial number of shares issued in those placements, which could add selling pressure. (SEC, SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.

ANL Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ANL Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.